C$12 0.5 4.4%
Last Trade - 07/08/20
| Market Cap | £175.0m |
| Enterprise Value | £167.5m |
| Revenue | £n/a |
| Position in Universe | 437th / 2679 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 26.4 | 68.8 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
| Last Annual | December 31st, 2019 |
| Last Interim | March 31st, 2020 |
| Incorporated | August 25, 2011 |
| Public Since | June 5, 2001 |
| No. of Shareholders: | n/a |
| No. of Employees: | 1 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Toronto Stock Exchange |
| Shares in Issue | 25,356,000 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 68 Tw Alexander Dr,PO Box 13628, DURHAM, 27709-3628, United States |
| Web | http://fennecpharma.com |
| Phone | +1 919 6364530 |
| Contact | () |
| Auditors | Haskell & White LLP |
As of 07/08/20, shares in Fennec Pharmaceuticals Inc are trading at C$12, giving the company a market capitalisation of £175.0m. This share price information is delayed by 15 minutes.
Shares in Fennec Pharmaceuticals Inc are currently trading at C$12 and the price has moved by 92% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fennec Pharmaceuticals Inc price has moved by 89.25% over the past year.
There are no analysts currently covering Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:
Fennec Pharmaceuticals Inc does not currently pay a dividend.
Fennec Pharmaceuticals Inc does not currently pay a dividend.
Fennec Pharmaceuticals Inc does not currently pay a dividend.
To buy shares in Fennec Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Fennec Pharmaceuticals Inc are currently trading at C$12, giving the company a market capitalisation of £175.0m.
Here are the trading details for Fennec Pharmaceuticals Inc:
Based on an overall assessment of its quality, value and momentum, Fennec Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Fennec Pharmaceuticals Inc are currently priced at C$12. At that level they are trading at 97.96% discount to the analyst consensus target price of 0.00.
Analysts covering Fennec Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.28 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fennec Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 47.26%. At the current price of C$12, shares in Fennec Pharmaceuticals Inc are trading at 39.55% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc's management team is headed by:
Here are the top five shareholders of Fennec Pharmaceuticals Inc based on the size of their shareholding:
